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Introduction
In sepsis, none of the prognostic biomarkers employed
have shown the necessary sensitivity and specificity to be
used routinely in clinical practice. In this research we ana-
lyze the relationship between proADM an other routinely
biomarkers employed in the management of severe sepsis
with mortality.
Methods
Prospective observational study. Plasmatic levels of
ProADM, C reactive protein (CRP) and procalcitonin
(PCT) and lactate in 110 consecutive patients admitted to
ICU with severe sepsis / septic shock at days 1st, 3rd and
7th after admission. Clinical and demographic data: age,
gender, comorbidities, APACHE II and SOFA scores.
Recruited period over 12 months. Statistical analysis: c2
test for categorical variables. AUROC for diagnostic pre-
diction of mortality. Spearman Karber test for correlations
between severity scores and biomarker levels. Multivariate
Cox regression analysis adjusted by age, gender and
APACHE II score to assess the impact of variables on
mortality across the time. Statistical significance: p < 0.05.
Results
110 patients. Male: 63%; APACHE II score: 21; SOFA
score: 8.5; Septic shock: 86%; ICU mortality: 32.7%;
Respiratory focus: 49%; Gram negatives: 33%; Gram
positives 30%.
ProADM was the biomarker showing better prognostic
accuracy in any time points analyzed by AUROC (p) for
28 day mortality, better than SOFA score at 1st and 7th
days of admission: At day 1st proADM = 0.80 (p < 0.001);
PCT = 0.62 (p = n.s); lactate = 0.71 (p < 0.001); CRP =
0.47 (p = n.s); SOFA 0.77 (p < 0.001); APACHE II = 0.72
(p < 0.001). At day 3rd proADM = 0.85 (p < 0.001);
PCT = 0.68 (p = 0.025); lactate = 0.78 (p < 0.001);
CRP = 0.49 (p =n.s); SOFA = 0.86 (p < 0.001). At day 7th
ProADM = 0.83 (p < 0.001); PCT = 0.67 (p = n.s); lactate =
0.62 (p = n.s); CRP = 0.61 (p=n.s); SOFA = 0.81 (p = 0.03).
Correlation test showed that proADM present the stron-
gest association with SOFA in all time points analyzed
[r; (p)]. At day 1st proADM = 0.71 ( < 0.001); PCT = 0.43
(p < 0.001); lactate = 0.50 (p < 0.001); CRP = 0.52 (p=n.s).
At day 3rd proADM = 0.69 (p < 0.001); PCT = 0.51
(p>0.001); lactate = 0.51 (p < 0.001); PCR = 0.23 (p = n.s).
At day 7th proADM = 0.63 (p < 0.001); PCT = 0.14 (p=n.s);
lactate = 0.40 (p= 0.02); CRP = 0.47 (p=n.s).
Multivariate Cox regression analysis showed proADM
as the only biomarker showing association with mortality
at day 28th in all time points analyzed [HR; p value; (CI)].
ProADM day 1st: [HR=1.085; p = 0.03; CI (1.05-1.170)];
proADM day 3rd [HR=1.051; p = 0.03; CI (1.001-1.104)];
proADM day 7th [HR=1.234; p= 0.001; CI (1.096-1.389)].
Conclusions
ProADM is a consistent marker of mortality risk and sever-
ity along time in severe sepsis and septic shock. This pro-
vides a selective advantage over other biomarkers as
prognostic tool. The inclusion in clinical practice could help
to intensivist, along with the rest of biomarkers and scores
of severity, for better optimization in making decisions for
management and establish prognosis of this disease.
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